| 1.17 -0.16 (-12.03%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.24 | 1-year : | 1.42 |
| Resists | First : | 1.06 | Second : | 1.22 |
| Pivot price | 1.07  |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 1.07 |
| MA(100) : | 1.24 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 18.4 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 3.39 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OCUP ] has closed above bottom band by 30.2%. Bollinger Bands are 27% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 0.97 - 0.97 | 0.97 - 0.98 |
| Close: | 0.98 - 0.99 | 0.99 - 1 |
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Fri, 25 Oct 2024
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire
Wed, 23 Oct 2024
Ocuphire Pharma acquires Opus Genetics - Healio
Wed, 23 Oct 2024
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Pharmaceutical Technology
Wed, 23 Oct 2024
Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition - Fierce Biotech
Wed, 23 Oct 2024
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
Tue, 22 Oct 2024
Ocuphire Pharma Announces Acquisition of Opus Genetics - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 8.6 (%) |
| Shares Short | 931 (K) |
| Shares Short P.Month | 1,030 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.55 |
| Profit Margin | -85.8 % |
| Operating Margin | -749 % |
| Return on Assets (ttm) | -21.4 % |
| Return on Equity (ttm) | -36.1 % |
| Qtrly Rev. Growth | -69.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.62 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -1.84 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 1.57 |
| Price to Cash Flow | -2.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|